menu
    • menu
    [{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.040000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Deep Track Capital","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Deep Track Capital"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Veverimer

    Menu

    Veverimer

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

                            Details : TRC101 (veverimer), a non-absorbed, orally administered polymer has ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD).

                            Brand Name : TRC101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 24, 2022

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Tr...

                            Details : TRC101 (veverimer), is novel, non-absorbed polymer that is designed to treat metabolic acidosis by binding hydrochloric acid in GIT and removing it from body through excretion in feces, thereby decreasing total amount of acid in body and increasing serum...

                            Brand Name : TRC101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 03, 2022

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tricida Announces Administrative Stop of the VALOR-CKD Trial

                            Details : TRC101 (veverimer), a novel, non-absorbed polymer that is designed to treat metabolic acidosis by binding hydrochloric acid in the gastrointestinal tract is specifically designed to combine high capacity and high selectivity for binding and removing hydr...

                            Brand Name : TRC101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 19, 2022

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tricida Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in Ukraine

                            Details : Veverimer, also known as TRC101, is a novel, non-absorbed polymer that is designed to treat metabolic acidosis by binding hydrochloric acid in the gastrointestinal tract and removing it from the body through excretion in the feces.

                            Brand Name : TRC101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 02, 2022

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tricida to Participate in Cowen 42nd Annual Health Care Conference

                            Details : Tricida investigational drug candidate, Veverimer, an orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD, is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer ...

                            Brand Name : TRC101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2022

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Deep Track Capital

                            Deal Size : $42.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Tricida Raises $42 Million in Registered Direct Equity Financing

                            Details : The net proceeds will be used to fund corporate operations, including the VALOR-CKD renal outcomes trial evaluating Veverimer, and are expected to extend Tricida’s financial runway into the first quarter of 2023.

                            Brand Name : TRC101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 15, 2021

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Deep Track Capital

                            Deal Size : $42.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tricida Granted Additional U.S. Patent Covering Composition of Matter of Veverimer

                            Details : The patent expands the composition of matter claims for veverimer to 2038 and extends the Tricida patent portfolio to a total of 210 patents in 49 different countries. Veverimer is a non-absorbed, orally-administered polymer for metabolic acidosis in pat...

                            Brand Name : TRC101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 03, 2021

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tricida Provides Update on FDA Interactions

                            Details : Tricida Has Received an Appeal Denied Letter from the Office of New Drugs of the FDA in Response to its Formal Dispute Resolution Request. The ongoing VALOR-CKD trial is a renal outcomes clinical trial designed to determine if veverimer slows CKD progres...

                            Brand Name : TRC101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 25, 2021

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Tricida, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tricida sinks as FDA rejection raises prospect of new trial

                            Details : Tricida has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for veverimer on August 21, 2020. The NDA was reviewed under the Accelerated Approval Program.

                            Brand Name : TRC101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 24, 2020

                            Lead Product(s) : Veverimer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth